Skip to Main Content

Paper Details

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients.
Am J Transplant
9
2023
Author NameAffiliation
Andrew PekoszJohns Hopkins University Bloomberg School of Public Health
Aaron A R TobianJohns Hopkins University School of Medicine
  • 1 - 2

Datasets

Release 1.2